Eosinopenia and routine inflammatory biomarkers are helpful for the diagnosis of infection in patients treated with IL-6 pathway antagonists

RMD Open. 2024 Feb 9;10(1):e003998. doi: 10.1136/rmdopen-2023-003998.

Audrey Glatre¹, Madeline Pascard², Maxime Hentzien³, Jean Hugues Salmon⁴, Amélie Servettaz^{5

6}, Ailsa Robbins^{7

6}

¹ Department of Internal Medicine, University Hospital Centre Reims, Reims, France.
² Department of Research and Public Health, University Hospital Centre Reims, Reims, France.
³ Department of Infectious diseases, University Hospital Centre Reims, Reims, France.
⁴ Rheumatology, University Hospital Centre Reims, Reims, France.
⁵ Immunologie Clinique, University Hospital Centre Reims, Reims, France.
⁶ EA 7509, Reims Champagne-Ardenne University, Reims, France.
⁷ Department of Internal Medicine, University Hospital Centre Reims, Reims, France arobbins@chu-reims.fr.

No abstract available

Keywords: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Biological Therapy.

Publication types